Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynne A Murray

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Frontiers in Pharmacology|February 3, 2016
Editorial: The Cell Types of FibrosisLynne A Murray
Pulmonary Pharmacology & Therapeutics|October 11, 2011
Commonalities between the pro-fibrotic mechanisms in COPD and IPFLynne A Murray
Inflammation & Allergy Drug Targets|March 23, 2013
Advances in industry for chronic respiratory diseasesLynne A Murray, Darryl A Knight
Frontiers in Pharmacology|January 7, 2016
Living with Fibrosis: From Diagnosis to Future HopeMatthew A Sleeman, Joseph Parker, Lynne A Murray
Current Opinion in Rheumatology|September 8, 2012
Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease?Lynne A Murray, Ami Rubinowitz, Erica L Herzog
Pulmonary Medicine|March 27, 2012
Smoking and idiopathic pulmonary fibrosisChad K Oh, Lynne A Murray, Nestor A Molfino
Inflammation & Allergy Drug Targets|March 23, 2013
Recombinant protein based therapeutics for IPFJoseph M Parker, Michael S Kramer, Lynne A Murray
Fibrogenesis & Tissue Repair|November 28, 2013
Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymesDeborah L Clarke, Alan M Carruthers, Tomas Mustelin, et al.
Pharmacology & Therapeutics|November 28, 2016
Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPFLynne A Murray, Chris Grainge, Peter A Wark, et al.
Pharmacology & Therapeutics|September 11, 2016
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?Deborah L Clarke, Lynne A Murray, Bruno Crestani, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Frontiers in Pharmacology|February 3, 2016
Editorial: The Cell Types of FibrosisLynne A Murray
Pulmonary Pharmacology & Therapeutics|October 11, 2011
Commonalities between the pro-fibrotic mechanisms in COPD and IPFLynne A Murray
Inflammation & Allergy Drug Targets|March 23, 2013
Advances in industry for chronic respiratory diseasesLynne A Murray, Darryl A Knight
Frontiers in Pharmacology|January 7, 2016
Living with Fibrosis: From Diagnosis to Future HopeMatthew A Sleeman, Joseph Parker, Lynne A Murray
Current Opinion in Rheumatology|September 8, 2012
Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease?Lynne A Murray, Ami Rubinowitz, Erica L Herzog
Pulmonary Medicine|March 27, 2012
Smoking and idiopathic pulmonary fibrosisChad K Oh, Lynne A Murray, Nestor A Molfino
Inflammation & Allergy Drug Targets|March 23, 2013
Recombinant protein based therapeutics for IPFJoseph M Parker, Michael S Kramer, Lynne A Murray
Fibrogenesis & Tissue Repair|November 28, 2013
Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymesDeborah L Clarke, Alan M Carruthers, Tomas Mustelin, et al.
Pharmacology & Therapeutics|November 28, 2016
Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPFLynne A Murray, Chris Grainge, Peter A Wark, et al.
Pharmacology & Therapeutics|September 11, 2016
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?Deborah L Clarke, Lynne A Murray, Bruno Crestani, et al.
Pageof 6